GILD 外国為替ニュース
Gilead Recalls COVID-19 Drug Veklury For Injection
Foster City, California-based Gilead Sciences, Inc. is recalling one lot of Veklury (remdesivir) for Injection 100 mg/vial for treating COVID-19, to the consumer level, due to the presence of a glass particle, according to the U.S. Food and Drug Administration. The recall involves Veklury (remdesivir 100mg for injection) with NDC 61958-2901-02, lot # 47035CFA and Expiration Date 11/2025.
RTTNews
|
96日前
Kite Says Tecartus Shows Prolonged OS In Adults With Refractory B-cell Acute Lymphoblastic Leukemia
Kite, a Gilead Sciences, Inc. Company (GILD), announced Monday updated, four-year overall survival (OS) data from the pivotal ZUMA-3 study evaluating the CAR T-cell therapy Tecartus (brexucabtagene autoleucel) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
RTTNews
|
208日前
Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1
Gilead Sciences, Inc. (GILD) announced Friday the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads.
RTTNews
|
246日前
Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years
Biopharmaceutical company Nurix Therapeutics, Inc. (NRIX) announced Tuesday that Gilead Sciences, Inc. (GILD) has elected to extend the research term of the companies' ongoing collaboration, originally established in 2019, by an additional two years.
RTTNews
|
270日前
Hookipa Pharma Says Gilead Purchases Addl. 15 Mln Shares Of HOOKIPA For Total Stake Of About 19.4%
Immunotherapeutics company Hookipa Pharma Inc. (HOOK) announced Thursday that Gilead Sciences, Inc. (GILD) has purchased 15 million shares of HOOKIPA's common stock for approximately $21.25 million, at a price of $1.4167 per share.
RTTNews
|
373日前
Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program
Gilead Sciences, Inc. (GILD) announced Tuesday an agreement with Holon, Israel-based cancer immunotherapy company Compugen Ltd. (CGEN) to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.
RTTNews
|
375日前
Gilead Exercises Option To License Nurix's Protein Degrader Molecule NX-0479
Biopharmaceutical companies Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc. (NRIX) announced Monday that Gilead has exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX-0479.
RTTNews
|
649日前
Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production
Biopharmaceutical company Kite, a Gilead Sciences, Inc. (GILD) company, announced Monday that the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.
RTTNews
|
817日前
Gilead Sciences Says CHMP Adopts Positive Opinion To Extend Indication Of Veklury
Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to extend the indication of Veklury (remdesivir) for the treatment of pediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19 as well as pediatric patients (4 weeks of age and older and weighing at least 3 kg) with SARS-CoV-2 with pneumonia who require supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at the start of treatment).
RTTNews
|
834日前
